Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million).

"This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus area of research as part of the Company’s strategy," Astellas

Read the full 447 word article

User Sign In